About: Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 24 July 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2018 (uk) article scientifique publié en 2018 (fr) artículu científicu espublizáu en xunetu de 2018 (ast) im September 2018 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 24 July 2018 (en)
publication date	wds:Q56521231-0E34CB91-1261-4B8A-BC86-2C47B84244E9
publication date	2018-07-24 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56521231-BFA4E908-B6FE-40DD-A171-3F2719758B2D
language of work or name	English
cites work	wds:Q56521231-691E6DC8-76EF-4ACD-8B09-29E6B234F5EC
cites work	Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
author name string	wds:Q56521231-6BEF3A76-761B-4755-ADF8-DECB2D55DD54 wds:Q56521231-B04ADF26-A82F-427C-AA74-9A7649820CD5
author name string	Joseph Makhema Roger L Shapiro
rdfs:label	Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception (en) Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception (nl)
skos:prefLabel	Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception (en) Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception (nl)
name	Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception (en) Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception (nl)
author	wds:Q56521231-CB90313A-2979-4B15-AF22-A75CBD769768
author	Rebecca Zash
title	wds:Q56521231-B4C884AC-1FB0-4E2F-8671-540FB82BFD2D
title	Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception (en)
page(s)	wds:Q56521231-B23F309A-FE0F-4C26-94C0-CB6306C5AFD0
page(s)	979-981
instance of	wds:Q56521231-0DE00926-F231-4E01-B3DF-DA0AD416D744
instance of	scholarly article
main subject	wds:Q56521231-8A93237E-99C9-402E-ACD1-15CD4487FB5D
main subject	wd:Q937224
PubMed ID	wds:Q56521231-B0C156DC-031D-4332-BAFF-41584A4634FE
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30037297
PubMed ID	30037297
published in	wds:Q56521231-97E74096-C6E2-470A-BC84-256EE939C520
published in	The New England Journal of Medicine
issue	wds:Q56521231-16BAD93A-BE9B-438A-B93B-47CFF74EF165
volume	wds:Q56521231-F0696E75-C4F6-429D-A8F7-83B0311BFB2E
issue	10
volume	379
DOI	wds:Q56521231-CFEEC473-6BFD-4838-ADB3-EAA7280F8F37
DOI	http://dx.doi.org/10.1056/NEJMC1807653
DOI	10.1056/NEJMC1807653
PMCID	wds:Q56521231-2E0591A4-77C8-4A1C-B8D7-B840079EAF17
PMCID	6550482
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56521231
is cites work of	High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities Dolutegravir in sub-Saharan Africa: context is crucial Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens Guidelines to support HIV-affected individuals and couples to achieve pregnancy safely: Update 2018. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors Post-marketing Surveillance of Pregnancy Outcomes With Dolutegravir Use Birth outcomes following antiretroviral exposure during pregnancy: Initial results from a pregnancy exposure registry in South Africa The far-reaching HAND of cART: cART effects on astrocytes Dolutegravir: advancing ethical research in pregnancy Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model Evaluating Neurodevelopmental Consequences of Perinatal Exposure to Antiretroviral Drugs: Current Challenges and New Approaches Perinatal outcomes of 25 hiv-infected pregnant women: hacettepe university experience Lessons from dolutegravir and neural tube defects Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection - 15 Jurisdictions, 2013-2017 Health Care Autonomy of Women Living with HIV Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO. A Multicenter Analysis of Elvitegravir Use During Pregnancy on HIV Viral Suppression and Perinatal Outcomes Dolutegravir Use at Conception - Additional Surveillance Data from Botswana "Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study) Modern HIV Therapy: Progress and Prospects Dolutegravir for pregnant women living with HIV Dolutegravir and neural tube defects: a new insight Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030 Mini review: Prevention of mother-child transmission of HIV: 25 years of continuous progress toward the eradication of pediatric AIDS? Switch to dolutegravir is well tolerated in Thais with HIV infection [Dolutegravir in acute HIV-1 infection: first reported case] Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling The management of treatment-experienced HIV patients (including virologic failure and switches) Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) Accelerating progress towards the elimination of mother-to-child transmission of HIV: a narrative review The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans Trajectories of fertility intentions among women living with HIV in South Africa

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software